

Contributors

Santa Cruz Biotechnology.
NBS Biologicals.

Publication/Creation

Santa Cruz, CA : Santa Cruz Biotechnology, [1996]

Persistent URL

<https://wellcomecollection.org/works/tbydgt dv>

License and attribution

Conditions of use: it is possible this item is protected by copyright and/or related rights. You are free to use this item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s).

Signal Transduction Research Antibodies




The Power to Question



Cell Signaling Pathways

Signaling from ligand-activated membrane receptors to the nucleus involves multiple, pathways functioning in concert to dictate cellular responses. The best studied of these include the JAK/Stat and *ras*/MAP kinase pathways (1). Insight into the JAK/Stat pathway was initially derived from studies of the interferon signaling pathways. For example, the binding of interferon α to its receptor results in the activation of two tyrosine


protein kinases, JAK1 and *tyk* 2. Subsequently, these kinases phosphorylate specific tyrosine residues of the Stat1 (either Stat1 α p91 or Stat1 β p84) and Stat2 (p113) transcription factors. The Stat 1 and 2 transcription factors form heterodimeric complexes which relocate to the nucleus, bind a protein designated p48, and bind to the ISRE DNA element to activate transcription of interferon α regulated target genes (1).



A broad range of ligand-induced responses are mediated via the JAK/Stat pathway. These extend not only to interferons and hematopoietic factors but also to growth factors specifically targeted to protein tyrosine kinase membrane receptors. To accommodate signaling from these diverse ligand activated receptors, diversity within the JAK/Stat signaling pathway is required. For instance, multiple members of the JAK family of protein kinases have been described, including JAK1, JAK2, JAK3, and *tyk 2* (2-4). Similarly, the Stat family of transcription factors identified to date is comprised of multiple members, including Stat1 α , 1 β , 2, 3, 4, 5, and IL-4 Stat (5-8), each of which can differentially regulate transcription through the formation of various combinations of homo- and heterodimeric complexes (1). Further diversity is derived through interactions with p48, and the related interferon response factor-1 (IRF-1) and IRF-2 proteins, that act to modify Stat transcription factor activity (9, 10).

The second well-studied signaling pathway involves activation of the MAP kinase phosphorylation cascade as a consequence of protein tyrosine kinase membrane receptor activation. Various growth factor ligands such as EGF, bind their cognate membrane receptors, induce

receptor subunit dimerization and transphosphorylation of critical tyrosine residues mapping within the intracellular domains of the receptor subunits. These phosphotyrosine residues, in turn, bind SH2 domain's of various signaling intermediates including those with catalytic activity such as PLC γ , PI 3 kinase, SH-PTP2 (*Syp*), and certain members of the JAK kinase family. Other signaling intermediates such as GRB2, GRB3 (*crk*) and GRB4 (*nck*), function to facilitate protein-protein interactions but themselves lack catalytic activity.



JAK/STAT SIGNALING PROTEINS

product	cat. #	isotype	applications	species
<i>tyk 2</i> (C-20)	sc-169	rabbit IgG	WB, IP, IHC	mouse, rat, human
JAK1 (Q-19)	sc-295	rabbit IgG	WB, IP, IHC	mouse, rat, human
JAK2 (C-20)	sc-294	rabbit IgG	WB, IP, IHC	mouse, rat, human
JAK3 (C-21)	sc-513	rabbit IgG	WB, IP, IHC	mouse, rat, human
Stat1 p91 (C-111)	sc-417	mouse IgG ₁	WB, IP, IHC, GS	mouse, rat, human
Stat1 p91 (C-24)	sc-345	rabbit IgG	WB, IP, IHC, GS	mouse, rat, human
Stat1 p84/p91 (C-136)	sc-464	mouse IgG ₁	WB, IP, IHC, GS	mouse, rat, human
Stat1 p84/p91 (E-23)	sc-346	rabbit IgG	WB, IP, IHC, GS	mouse, rat, human
Stat2 p113 (C-20)	sc-476	rabbit IgG	WB, IP, IHC, GS	mouse, rat, human
Stat3 (K-15)	sc-483	rabbit IgG	WB, IP, IHC, GS	mouse, rat, human
Stat3 (C-20)	sc-482	rabbit IgG	WB, IHC, GS	mouse, rat, human
Stat4 (L-18)	sc-485	rabbit IgG	WB, IP, IHC, GS	mouse, rat, human
Stat4 (C-20)	sc-486	rabbit IgG	WB, IP, IHC, GS	mouse, rat, human
IRF-1 (C-20)	sc-497	rabbit IgG	WB, IHC, GS	mouse, rat, human
IRF-2 (C-19)	sc-498	rabbit IgG	WB, IHC, GS	mouse, rat, human
ISGF-3 γ p48 (C-20)	sc-496	rabbit IgG	WB, IHC, GS	mouse and rat

WB - Western blotting, IP - Immunoprecipitation, IHC - Immunohistochemistry, GS - Gel Supershift

SH2/SH3 SIGNALING INTERMEDIATES

product	cat. #	isotype	applications	species
GRB2 (C-23)	sc-255	rabbit IgG	WB, IP, IHC	mouse, rat, human
GRB2 (217)	sc-422	rabbit IgG	WB, IP, IHC	mouse, rat, human
GRB2 (1-68)	sc-503	mouse IgG	WB, IP, IHC	mouse, rat, human
<i>vav</i> (C-14)	sc-132	rabbit IgG	WB, IP, IHC	mouse, rat, human
ZAP-70 (485)	sc-157	rabbit IgG	WB, IP, IHC	mouse, rat, human
ZAP-70 (LR)	sc-574	rabbit IgG	WB, IP, IHC	mouse, rat, human
<i>syk</i> (LR)	sc-573	rabbit IgG	WB, IP, IHC	mouse, rat, human
<i>Sbc</i> (C-20)	sc-288	rabbit IgG	WB, IP, IHC	mouse, rat, human
<i>csk</i> (C-20)	sc-286	rabbit IgG	WB, IP, IHC	mouse, rat, human
<i>ctk</i> (C-20)	sc-470	rabbit IgG	WB, IP, IHC	mouse and rat
<i>lck</i> (3A5)	sc-433	mouse IgG _{2b}	WB, IP, IHC	mouse, rat, human
<i>lck</i> (2102)	sc-13	rabbit IgG	WB, IP, IHC	mouse, rat, human
<i>c-yes</i> (3)	sc-14	rabbit IgG	WB, IP, IHC	mouse, rat, human
<i>lyn</i> (44)	sc-15	rabbit IgG	WB, IP, IHC	mouse, rat, human
<i>c-src</i> (N-16)	sc-19	rabbit IgG	WB, IP, IHC	mouse, rat, human
<i>fyn</i> (FYN3)	sc-16	rabbit IgG	WB, IP, IHC	mouse, rat, human
<i>fyn</i> (15)	sc-434	mouse IgG ₁	WB, IP, IHC	mouse, rat, human
<i>bck</i> (N-30)	sc-72	rabbit IgG	WB, IP, IHC	mouse, rat, human


WB - Western blotting, IP - Immunoprecipitation, IHC - Immunohistochemistry

The binding of signaling molecules, such as GRB2, to receptors is either direct, or indirect. Indirect binding is mediated either by protein tyrosine phosphatases (11, 12) or by a class of proteins of which *Sbc*, *Sbb*, (13, 14) and the insulin receptor substrate-1, IRS-1, (15, 16) proteins represent prototypes. These latter proteins bind activated membrane receptors through their SH2 domains and are themselves phosphorylated on tyrosine residues to which the various signaling intermediates then bind (13-16). In addition to the broad family of transmembrane protein tyrosine kinase receptors, a second class of protein tyrosine kinases are intracellular but function in a manner analogous to the intracellular domains of the transmembrane receptors. These latter kinases include members of the *src* gene family and functionally-related proteins such as ZAP-70 and *syk* (17, 18).

In its activated form, GRB2 binds the guanine nucleotide exchange protein, Sos, through the binding of its SH3 domain to Sos proline rich sequences. Sos mediates *ras* protein activation by facilitating exchange of GDP for GTP, and *ras*, in turn, activates

both MEK kinase (19) and *raf* which translocates to the cell membrane (20, 21), binds 14-3-3 (22, 23) and, in its activated form, functions as a MEK kinase converting MEK from its inactive to activated form through phosphorylation at ser-218 and ser-222 (24, 25). In addition, *ras* has recently been shown to interact directly with the catalytic subunit of PI 3 kinase in a GTP-dependent manner (26).

Activated MEK, also designated MAP kinase kinase, functions to activate MAP kinases (ERK proteins) via



phosphorylation at a tyr-183/thr-185 regulatory motif. In turn MAP kinases phosphorylate the *elk* transcription factor which upregulates transcription of *fos* (27). A MAP kinase related protein designated *jun* kinase-1, or JNK 1, also activated by phosphorylation of a tyr-183/thr-185 motif, functions to activate a second member of the AP-1 transcription factor family, *jun*, via phosphorylation of ser 63 and ser 73 residues (28-30) while *fos* regulating kinase (FRK) functions to activate *fos* via phosphorylation of thr-232 (31). An additional MAP kinase related protein, p38, with a

similar tyr/thr phosphorylation regulatory motif, has been identified as the mammalian homolog of the yeast protein, HOG-1 (32).

Cellular responses to ligand activation including differentiation, mitotic stimulation/arrest, or apoptosis are ultimately determined by the balance of signaling between diverse pathways such as those described above. Much remains to be done to further map these pathways and to delineate their role in cell signaling.

MAP KINASE SIGNALING PATHWAY

product	cat. #	isotype	applications	species
v-H-ras (259)	sc-35	rat IgG ₁	WB, IP, IHC	mouse, rat, human
ras GAP (B4F8)	sc-63	mouse IgG _{2a}	WB, IP, IHC	mouse, rat, human
raf-1 (C-20)	sc-227	rabbit IgG	WB, IP, IHC	mouse, rat, human
raf-A (C-20)	sc-408	rabbit IgG	WB, IP, IHC	mouse, rat, human
raf-B (C-19)	sc-166	rabbit IgG	WB, IP, IHC	mouse, rat, human
MEK kinase (C-22)	sc-252	rabbit IgG	WB, IP, IHC	mouse, rat, human
MEK kinase (1-9C-2A)	sc-449	mouse IgG ₁	WB, IP	human specific
MEK-1 (12-B)	sc-436	rabbit IgG	WB, IP, IHC	mouse, rat, human
MEK-1 (C-18)	sc-219	rabbit IgG	WB, IHC	mouse, rat, human
MEK-2 (C-16)	sc-525	rabbit IgG	WB, IP, IHC	mouse, rat, human
ERK 1 (C-16)	sc-93	rabbit IgG	WB, IP, IHC	mouse, rat, human
ERK 1 (K-23)	sc-94	rabbit IgG	WB, IHC	mouse, rat, human
ERK 2 (C-14)	sc-154	rabbit IgG	WB, IP, IHC	mouse, rat, human
JNK 1 (N-19)	sc-473	rabbit IgG	WB, IP, IHC	mouse, rat, human
JNK 1 (C-17)	sc-474	rabbit IgG	WB, IP, IHC	mouse, rat, human

AP-1 TRANSCRIPTION FACTORS

product	cat. #	isotype	applications	species
c-fos (4)	sc-52	rabbit IgG	WB, IHC, GS	mouse, rat, human
c-fos (K-25)	sc-253	rabbit IgG	WB, IP, IHC, GS	mouse, rat, human
c-fos (4-10G)	sc-413	mouse IgG _{2a}	WB, IP, GS	mouse, rat, human
fos B (102)	sc-48	rabbit IgG	WB, IP, GS	mouse, rat, human
c-jun/AP-1 (D)	sc-44	rabbit IgG	WB, IP, GS	mouse, rat, human
c-jun/AP-1 (N)	sc-45	rabbit IgG	WB, IP, IHC, GS	mouse, rat, human
jun B (N-17)	sc-46	rabbit IgG	WB, IP, IHC, GS	mouse, rat, human
jun D (329)	sc-74	rabbit IgG	WB, IP, IHC, GS	mouse, rat, human

WB - Western blotting, IP - Immunoprecipitation, IHC - Immunohistochemistry, GS - Gel Supershift

Current References

- Darnell, J.E. Jr., Kerr, I.M., and Stark, G.R. 1994. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. *Science* **264**: 1415-1421.
- Nicholson, S.E., Oates, A.C., Harpur, A.G., Ziemiecki, A., Wilks, A.F., and Layton, J.E. 1994. Tyrosine kinase JAK1 is associated with the granulocyte-colony-stimulating factor receptor and both become tyrosine-phosphorylated after receptor activation. *Proc. Natl. Acad. Sci. USA* **91**: 2985-2988.
- Witthuhn, B.A., Silvennoinen, O., Miura, O., Lai, K.S., Cwik, C., Liu, E.T., and Ihle, J.N. 1994. Involvement of the Jak-3 Janus kinase in signalling by interleukins 2 and 4 in lymphoid and myeloid cells. *Nature* **370**: 153-157.
- Johnston, J.A., Kawamura, M., Kirken, R.A., Chen, Y.-Q., Blake, T.B., Shibuya, K., Ortaldo, J.R., McVicar, D.W., and O'Shea, J.J. 1994. Phosphorylation and activation of the Jak-3 Janus kinase in response to interleukin-2. *Nature* **370**: 151-153.
- Akira, S., Nishio, Y., Inoue, M., Wang, X.-J., Wei, S., Matsusaka, T., Yoshida, K., Sudo, T., Naruto, M., and Kishimoto, T. 1994. Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. *Cell* **77**: 63-71.
- Yamamoto, K., Quelle, F.W., Thierfelder, W.E., Kreider, B.L., Gilbert, D.J., Jenkins, N.A., Copeland, N.G., Silvennoinen, O., and Ihle, J.N. 1994. Stat4, a novel gamma interferon activation site-binding protein expressed in early myeloid differentiation. *Mol. Cell. Biol.* **14**: 4342-4349.
- Zhong, Z., Wen, Z., and Darnell, J.E. Jr. 1994. Stat3 and Stat4: members of the family of signal transducers and activators of transcription. *Proc. Natl. Acad. Sci. USA* **91**: 4806-4810.
- Hou, J., Schindler, U., Henzel, W.J., Ho, T.C., Brasseur, M., and McKnight, S.L. 1994. An interleukin-4-induced transcription factor: IL-4 Stat. *Science* **265**: 1701-1708.
- Tanaka, N., Ishihara, M., Kitagawa, M., Harada, H., Kimura, T., Matsuyama, T., Lamphier, M.S., Aizawa, S., Mak, T.W., and Taniguchi, T. 1994. Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1. *Cell* **77**: 829-839.
- Harada, H., Takahashi, E.-I., Itoh, S., Harada, K., Hori, T.-A., and Taniguchi, T. 1994. Structure and regulation of the human interferon regulatory factor 1 (IRF-1) and IRF-2 genes: implications for a gene network in the interferon system. *Mol. Cell. Biol.* **14**: 1500-1509.
- Li, W., Nishimura, R., Kashishian, A., Batzer, A.G., Kim, W.J.H., Cooper, J.A., and Schlessinger, J. 1994. A new function for a phosphotyrosine phosphatase: linking GRB2-Sos to a receptor tyrosine kinase. *Mol. Cell. Biol.* **14**: 509-517.
- den Hertog, J., Tracy, S., and Hunter, T. 1994. Phosphorylation of receptor protein-tyrosine phosphatase alpha on Tyr789, a binding site for the SH3-SH2-SH3 adaptor protein GRB-2 in vivo. *EMBO J.* **13**: 3020-3032.
- Sasaoka, T., Rose, D.W., Jhun, B.H., Saltiel, A.R., Draznin, B., and Olefsky, J.M. 1994. Evidence for a functional role of Shc proteins in mitogenic signaling induced by insulin, insulin-like growth factor-1, and epidermal growth factor. *J. Biol. Chem.* **269**: 13689-13694.
- Pronk, G.J., de Vries-Smits, A.M.M., Buday, L., Downward, J., Maassen, J.A., Medema, R.H., and Bos, J.L. 1994. Involvement of Shc in insulin- and epidermal growth factor-induced activation of p21^{ras}. *Mol. Cell. Biol.* **14**: 1575-1581.
- Myers, M.G. Jr., Wang, L.M., Sun, X.J., Zhang, Y., Yenush, L., Schlessinger, J., Pierce, J.H., and White, M.F. 1994. Role of IRS-1-GRB-2 complexes in insulin signaling. *Mol. Cell. Biol.* **14**: 3577-3587.
- Sugimoto, S., Wandless, T.J., Shoelson, S.E., Neel, B.G., and Walsh, C.T. 1994. Activation of the SH2-containing protein tyrosine phosphatase, SH-PTP2, by phosphotyrosine-containing peptides derived from insulin receptor substrate-1. *J. Biol. Chem.* **269**: 13614-13622.
- Couture, C., Baier, G., Altman, A., and Mustelin, T. 1994. p56^{lck}-independent activation and tyrosine phosphorylation of p72^{src} by T-cell antigen receptor/CD3 stimulation. *Proc. Natl. Acad. Sci. USA* **91**: 5301-5305.
- Chan, A.C., van Oers, N.S.C., Tran, A., Turka, L., Law, C.-L., Ryan, J.C., Clark, E.A., and Weiss, A. 1994. Differential expression of ZAP-70 and Syk protein tyrosine kinases, and the role of this family of protein tyrosine kinases in TCR signaling. *J. Immunol.* **152**: 4758-4766.
- Lange-Carter, C.A. and Johnson, G.L. 1994. Ras-dependent growth factor regulation of MEK kinase in PC12 cells. *Science* **265**: 1458-1461.
- Levers, S.J., Paterson, H.F., and Marshall, C.J. 1994. Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane. *Nature* **369**: 411-414.
- Stokoe, D., Macdonald, S.G., Cadwallader, K., Symons, M., and Hancock, J.F. 1994. Activation of Raf as a result of recruitment to the plasma membrane. *Science* **264**: 1463-1467.
- Irie, K., Gotoh, Y., Yashar, B.M., Errede, B., Nishida, E., and Matsumoto, K. 1994. Stimulatory effects of yeast and mammalian 14-3-3 proteins on the Raf protein kinase. *Science* **265**: 1716-1719.
- Freed, E., Symons, M., Macdonald, S.G., McCormick, F., and Ruggieri, R. 1994. Binding of 14-3-3 proteins to the protein kinase Raf and effects on its activation. *Science* **265**: 1713-1716.
- Yan, M. and Templeton, D.J. 1994. Identification of 2 serine residues of MEK-1 that are differentially phosphorylated during activation by raf and MEK kinase. *J. Biol. Chem.* **269**: 19067-19073.
- Huang, W. and Erikson, R.L. 1994. Constitutive activation of Mek1 by mutation of serine phosphorylation sites. *Proc. Natl. Acad. Sci. USA* **91**: 8960-8963.
- Rodriguez-Viciana, P., Warne, P.H., Dhand, R., Vanhaesebroeck, B., Gout, I., Fry, M.J., Waterfield, M.D., and Downward, J. 1994. Phosphatidylinositol-3-OH kinase as a direct target of Ras. *Nature* **370**: 527-532.
- Rao, V.N. and Reddy, E.S.P. 1994. *elk-1* proteins interact with MAP kinases. *Oncogene* **9**: 1855-1860.
- Westwick, J.K., Cox, A.D., Der, C.J., Cobb, M.H., Hibi, M., Karin, M., and Brenner, D.A. 1994. Oncogenic Ras activates c-Jun via a separate pathway from the activation of extracellular signal-regulated kinases. *Proc. Natl. Acad. Sci. USA* **91**: 6030-6034.
- Dérjard, B., Hibi, M., Wu, I.-H., Barrett, T., Su, B., Deng, T., Karin, M., and Davis, R.J. 1994. JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. *Cell* **76**: 1025-1037.
- Kyriakis, J.M., Banerjee, P., Nikolakaki, E., Dai, T., Ruble, E.A., Ahmad, M.F., Avruch, J., and Woodgett, J.R. 1994. The stress-activated protein kinase subfamily of c-Jun kinases. *Nature* **369**: 156-160.
- Deng, T. and Karin, M. 1994. c-Fos transcriptional activity stimulated by H-Ras-activated protein kinase distinct from JNK and ERK. *Nature* **371**: 171-175.
- Han, J., Lee, J.-D., Bibbs, L., and Ulevitch, R.J. 1994. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. *Science* **265**: 808-811.

Send me information on the following products:

Write **catalog number** in the boxes above

- ☐ Please send me your 1994-95 Research Product Catalog.
- ☐ Add me to your mailing list.
- ☐ Add me to your fax bulletin to receive:
- complimentary product samples
 - new product releases
 - technical updates
- ☐ Remove me from your mailing list.

Name

Institution

Department

Address

City

State

Zip

Phone

Fax

International Distributors:

Australia, Lab Supply Australia, (02) 550-3222; Austria, Dipl. Ing. Zoltán SZABÓ, (0222)-409 3961-0; Belgium, SanverTECH N.V., 03-454 00 66; Brasil, Genoma (031) 275-1240; China, Golden Bridge International, (01) 513 9712; Finland, YAKEMIA Oy, (90) 708 081; France, Tebu, (1) 34 84 62 52; Germany, IC Chemikalien GmbH, 089 9 61 20 51; Greece, BioAnalytica, 030-1-6436138; Hong Kong, TWC Biosearch International, 852-649-9988; India, Biotech India (542) 311 473; Ireland, Medlab Biotech, 353-1-295-2101; Israel, ENCO Scientific Services, Ltd., 972-3-9349922; Italy, Genzyme s.r.l., 02/6127621; Japan, Toyobo Co., Ltd., 81 6 348 3786; Korea, Koram Biotech Corporation, 82 (02) 556-0311; Netherlands, SanverTECH N.V., 076-22 62 57; New Zealand, Labsupply Pierce (NZ) Ltd., (64) 09-443-5867; Poland, The Trade Company "AMX", 42-45-00-64; Portugal, Quimigranel, Ida, 01-858 1564; Singapore, Indonesia, Malaysia, Innovative Biotech Pte Ltd., (65) 779 1919; South Africa, Whitehead Scientific, 21 981 1560; Spain, Quimigranel s.a., 34 (91) 556 1614; Sweden, Norway, Denmark, Iceland, SDS - Scandinavian Diagnostic Services, 46(0) 346 83050; Switzerland, Dr. Glaser AG Basel, 0041/61 271 63 80; Taiwan, Hung Jing Co., Ltd., 886-2-3930185; Taiwan, Union Biomedical, Inc., 02-368-3600; Thailand, Diagnostic Biotechnology, (662) 284-0309; United Kingdom, NBS Biologicals, (0707) 275733

T A C R U Z

nine kinases

, PKC (α , β I, β II, γ , θ , δ ,
ase p85, p110, MAP kinase,
EK kinase and JNK1

ermediates

ck, crk, crk-L, dbp, ras GAP,
7 (γ 1, γ 2, β 1, β 2, β 3, β 4,

ific transcripton

1, myf-5, myf-6, MEF-2,
2, E47 and Id (1-4)

essors

130, WAF1/Cip1 p21, p53,
and bMSH2

lated proteins

53, IRF-1, IRF-2

(1st author) referencing
uary 1995.

products from Santa
rldwide in the January

3.

r choice.

e; \$25

Antibodies to:

- **cell membrane receptors**

trk, *EGF* (R), *neu*, *flt*, *flk-1*, *flt-4*, *flt-3/flk-2*, *STK-1*, *met*, *IL-3* (R), *IL-5* (R), *GM-CSF* (R), *FGF* (R), *PDGF* (R)-A, *PDGF* (R)-B, *ret*, *IGF-I* (R), *kit*, *tie*, *tek* and *erb B4*

- **cell cycle proteins**

cyclin A, *cyclin B*, *cyclin D1*, *cyclin D2*, *cyclin D3*, *cyclin E*, *cyclin G*, *PCNA*, *cdc2 p34*, *cdk2*, *cdk4*, *cdk5*, *cdk6* and *PITALRE*

- **transcription factors**

NFκB p65, *p50*, *p52*, *rel*, *rel B*, *IκB-α/MAD-3*, *WT*, *E2F-1*, *E2F-4*, *Sp1*, *AP-2*, *YY1*, *oct-1*, *oct-2*, *Max*, *Mad*, *CREB*, *ATF* (1-4), *TFIIB*, *TFIID*, *GAL4 (DBD)*, *GAL4 (TA)*, *maf* and *NF-E2*

- **GTP binding proteins**

H-ras, *N-ras*, *K-ras*, *rho A*, *rho B*, *rab 1*, *rab 2*, *rab 3A*, *rab 3B*, *rab 4*, *rab 5A*, *rab 6*, *rab 8*, *rap 1*, *rap 2*, *rac 1*, *rac 2*, *rho GDI*, *heterotrimeric G protein α, β and γ subunits*

- **serine/threonine kinases**

raf-1, *raf A*, *raf B*, *PKC* (α , β I, β II, γ , θ , δ , ϵ , η , ζ), *PI 3 kinase p85*, *p110*, *MAP kinase*, *MEK-1*, *MEK-2*, *MEK kinase* and *JNK1*

- **signaling intermediates**

GRB2, *vav*, *Sos*, *nck*, *crk*, *crk-L*, *dbi*, *ras GAP*, *ras-GRF*, and *PLC* (γ 1, γ 2, β 1, β 2, β 3, β 4, δ 1, δ 2)

- **muscle-specific transcription factors**

Myo D, *myogenin*, *myf-5*, *myf-6*, *MEF-2*, *xMEF-2*, *HEB*, *E12*, *E47* and *Id* (1-4)

- **tumor suppressors**

Rb p110, *p107*, *p130*, *WAF1/Cip1 p21*, *p53*, *p27*, *MTS1 p16* and *bMSH2*

- **apoptosis-related proteins**

bax, *bcl 2*, *myc*, *p53*, *IRF-1*, *IRF-2* and *GADD 153*

Santa Cruz Investigator Award

- Apply for an Investigator Award by submitting your accepted paper (1st author) referencing the use of any Santa Cruz product. Publication must be prior to January 1995.
- The winner will receive a research credit for a total of ten antibody products from Santa Cruz. The credit is valid during 1995. Winner to be announced worldwide in the January What's New and the new 1995 Santa Cruz Research Product Catalog.
- All entrants will receive credit for a complimentary antibody of their choice.

PY-20 Special with Any Antibody Purchase; \$25

- p-Tyr (PY-20), sc-508, 200 µg/ml

NO POSTAGE
NECESSARY
IF MAILED
IN THE
UNITED STATES



BUSINESS REPLY MAIL

FIRST-CLASS MAIL PERMIT NO. 41 SANTA CRUZ CA

POSTAGE WILL BE PAID BY THE ADDRESSEE

We have moved !

NBS Biologicals
14 Tower Square
Huntingdon

Cambs PE18 7DT

T 01480 433875 F 01480 459868

SANTA CRUZ CA 95060-9851



100 Easton Road
LONDON NW1 2BE

Santa Cruz Biotechnology, Inc.

2161 Delaware Avenue
Santa Cruz, CA 95060
408.457.3800
800.457.3801
Fax 408.457.3801
Internet: scbt@netcom.com



The Power to Question

10-1-95



Santa Cruz Biotechnology, Inc.

2161 Delaware Avenue
Santa Cruz, CA 95060
408.457.3800
800.457.3801
Fax 408.457.3801
Internet scbt@netcom.com

The Power to Question

04001
Mr S Lowther
Assistant Librarian
Modern Medicine
The Wellcome Institute
183 Euston Road
LONDON NW1 2BE



WE CAN GET A LOT OF



10-1-95